Anti-angiogenic polypeptides

Details Anti-angiogenic polypeptides Anti-angiogenic polypeptides

2008-07-31

2009-12-01

Yaen, Christopher H (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

07626008

ABSTRACT:
Anti-angiogenic polypeptides A61or p22 are disclosed. Also disclosed are methods of making the polypeptides and methods of treating subjects having angiogenic diseases or conditions.

REFERENCES:
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: WO 99/16889 (1999-04-01), None
patent: WO 02/44328 (2002-06-01), None
Overbeek (1994, “Factors affecting transgenic animal production,” Transgenic animal technology, pp. 96-98).
Wall, 1996 Theriogenology, vol. 45, pp. 57-68.
Houdebine, 1994, J. Biotech. vol. 34, pp. 269-287.
Cameron, 1997, Molec. Biol. 7, pp. 253-265.
Niemann, 1997, Transg. Res. 7, pp. 73-75.
Mullins 1993, Hypertension, vol. 22, pp. 630-633.
Mullins 1990, Nature, vol. 344, 541-544.
Hammer 1990, Cell, vol. 63, 1099-1112.
Mullins, 1989, EMBO J., vol. 8, pp. 4065-4072.
Taurog, 1988, Jour. Immunol., vol. 141, pp. 4020-4023.
Mullins 1996, J. Clin. Invest. vol. 98, pp. S37-S40.
Menhart, et al., “Construction, expression, and purification of recombinant kringle 1 of human plasminogen and analysis of its interaction with w-amino acid,” Biochemistry 30:1948-1957, 1991.
Cao et al., “Kringle domains of human angiostain. Characterization of the anti-prolferative activity on endothelial cells.” J Biol Chem., 1996, vol. 271, No. 46, pp. 29461-29467.
Heidtmann et al., “Generation of angiostain-like fragments from plasminogen by prostate-specific antigen.” Br J Cancer, 1999, vol. 81, No. 8, pp. 1269-1273.
Macdonald et al., “The tumor-supressing activity of angiostain protein resides within kringles 1 to 3.” Biochem Biophys Res Commun., 1999, vol. 254, No. 2, pp. 469-477.
Soff, “Angiostain and angiostatin-related proteins.” Cancer Metastases Rev., 2000, vol. 19, No. (1-2), pp. 97-107.
Ballagamba et al, “Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding.” J Biol Chem., 1997, vol. 272, No. 6, pp. 3195-3199.
Brooks et al., “Ca2+-dependent and phospholipid-independent binding of annexin 2 and annexin 5.” Biochem J., 2002, vol. 367, Pt 3, pp. 895-900.
Caplan et al, “Regulation of annexin A2 by reversible glutathionylation.” J Biol Chem., 2004, vol. 279, No. 9, pp. 7740-7750.
Choi et al., “Annexin II tetramer inhibits plasmin-dependent fibrinolysis.” Biochemistry, 1998, vol. 37, No. 2, pp. 648-655.
Choi et al., “Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer.” J Biol Chem., 2001, vol. 276, No. 27, pp. 25212-25221.
Choi et al., “p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.” FASEB J., 2003, vol. 17, No. 2, pp. 235-246.
Falcone et al., “Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen.” J Biol Chem., 1998, vol. 273, No. 47, pp. 31480-31485.
Filipenko et al., “Characterization of the Ca2+-binding sites of annexin II tetramer.” J Biol Chem., 2000, vol. 275, No. 49, pp. 38877-38884.
Filipenko et al., “The C terminus of annexin II mediates binding to F-actin.” J Biol Chem., 2001, vol. 276, No. 7, pp. 5310-5315.
Filipenko et al., “Annexin A2 is a novel RNA-binding protein.” J Biol Chem., 2004, vol. 279, No. 10, pp. 8723-8731.
Fitzpatrick et al., “Fucoidan-dependent conformational changes in annexin II tetramer.” Biochemistry, 2000, vol. 39, No. 9, pp. 2140-2148.
Fitzpatrick et al., “Regulation of plasmin activity by annexin II tetramer.” Biochemistry, 2000, vol. 39, No. 5, pp. 1021-1028.
Fogg et al., “The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase.” Biochemistry, 2002, vol. 41, No. 15, pp. 4953-4961.
Gately et al., “The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.” Proc Natl Acad Sci U S A, 1997, vol. 94, No. 20, pp. 10868-10872.
Johnsson et al., “Alkylation of cysteine 82 of p11 abolishes the complex formation with the tyrosine-protein kinase substrate p36 (annexin 2, calpactin 1, lipocortin 2).” J Biol Chem., 1990, vol. 265, No. 24, pp. 14464-14468.
Kang et al., “Characterization of human recombinant annexin II tetramer purified from bacteria: role of N-terminal acetylation.” Biochemistry, 1997, vol. 36, No. 8, pp. 2041-2050.
Kassam et al. “Characterization of the heparin binding properties of annexin II tetramer.” J Biol Chem., 1997, vol. 272, No. 24, pp. 15093-15100.
Kassam et al., “The role of annexin II tetramer in the activation of plasminogen.” J Biol Chem., 1998, vol. 273, No. 8, pp. 4790-4799.
Kassam et al., “The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation.” Biochemistry, 1998, vol. 37, No. 48, pp. 16958-16966.
Kwon et al., “Identification of annexin II heterotetramer as a plasmin reductase.” J Biol Chem., 2002, vol. 277, No. 13, pp. 10903-10911.
Lay et al., “Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.” Nature, 2000, vol. 408, No. 6814, pp. 869-873.
MacLeod et al., “Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin.” J Biol Chem., 2003, vol. 278, No. 28, pp. 25577-25584.
Stathakis et al., “Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.” J Biol Chem., 1997, vol. 272, No. 33, pp. 20641-20645.
Stathakis et al., “Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.” J Biol Chem., 1999, vol. 274, No. 13, pp. 8910-8916.
Teratani et al., “Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma.” Cancer Lett., 2002, vol. 175, No. 1, pp. 71-77.
Yao et al., “Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity.” J Biol Chem., 1999, vol. 274, No. 24, pp. 17202-17208.
Zhang et al., “RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.” J Biol Chem., 2004, vol. 279, No. 3, pp. 2053-2062.
International Search Report for PCT/US01/44515, dated Apr. 13, 2007, 4 pages.

Affiliated with

Also associated with

Rating

Anti-angiogenic polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-angiogenic polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-angiogenic polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4149270